EVERSENSE CONTINUOUS GLUCOSE MONITORING SYSTEM

Continuous Glucose Monitor, Implanted, Adjunctive Use

FDA Premarket Approval P160048

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the eversense cgm system. The device is indicated for continually measuring glucose levels in adults (18 years and older) with diabetes for up to 90 days. The system is intended to:1) provide real-time glucose readings;2) provide glucose trend information; and3) provide alerts for the detection and prediction of episodes of low blood glucose (hypoglycemia) and high blood glucose (hyperglycemia). The system is a prescription device. Historical data from the system can be interpreted to aid in providing therapy adjustments. These adjustments should be based on patterns seen over time. The system is indicated for use as an adjunctive device to complement, not replace, information obtained from standard home blood glucose monitoring devices.

DeviceEVERSENSE CONTINUOUS GLUCOSE MONITORING SYSTEM
Classification NameContinuous Glucose Monitor, Implanted, Adjunctive Use
Generic NameContinuous Glucose Monitor, Implanted, Adjunctive Use
ApplicantSENSEONICS, INCORPORATED
Date Received2016-10-26
Decision Date2018-06-21
Notice Date2018-07-24
PMAP160048
SupplementS
Product CodeQCD
Docket Number18M-2463
Advisory CommitteeClinical Chemistry
Expedited ReviewNo
Combination Product No
Applicant Address SENSEONICS, INCORPORATED 20451 Seneca Meadows Parkway germantown, MD 20876-7005
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Post-Approval Study:Show Report Schedule and Study Progress
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P160048Original Filing
S017 2020-11-12 30-day Notice
S016
S015
S014 2019-08-27 Normal 180 Day Track No User Fee
S013 2019-07-31 30-day Notice
S012
S011 2019-06-27 Normal 180 Day Track
S010 2019-06-24 30-day Notice
S009 2019-05-28 30-day Notice
S008 2018-12-11 Real-time Process
S007 2018-11-28 Normal 180 Day Track No User Fee
S006
S005 2018-09-11 Real-time Process
S004 2018-09-07 Real-time Process
S003 2018-08-27 Normal 180 Day Track No User Fee
S002 2018-08-07 Normal 180 Day Track
S001 2018-07-20 Normal 180 Day Track No User Fee

NIH GUDID Devices

Device IDPMASupp
00817491021908 P160048 000
00817491020819 P160048 000
00817491020826 P160048 000
00817491021328 P160048 000
00817491021304 P160048 000
00817491021311 P160048 000
00817491021335 P160048 000
00817491021397 P160048 000
00817491021403 P160048 000
00817491022493 P160048 000
00817491021458 P160048 000
00817491021441 P160048 000
00817491021434 P160048 000
00817491021427 P160048 000
00817491021410 P160048 000
00817491022370 P160048 006
00817491022523 P160048 006
00817491022516 P160048 006
00817491023605 P160048 006
00817491023612 P160048 006
00817491022387 P160048 006
00817491022349 P160048 008
00817491022363 P160048 008
00817491022356 P160048 008
00817491023858 P160048 016
00817491022882 P160048 016
00817491022905 P160048 016
00817491022912 P160048 016
00817491022929 P160048 016
00817491022936 P160048 016
00817491022950 P160048 016
00817491022967 P160048 016
00817491022974 P160048 016
00817491021342 P160048 016
00817491023063 P160048 016
00817491023520 P160048 016
00817491023537 P160048 016
00817491023841 P160048 016

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.